AbbVie Evaluates Dividend Growth Prospects Amid Shrinking Humira Revenues

As patent expirations erode cash flows from its blockbuster drug Humira, pharmaceutical giant AbbVie faces scrutiny over whether it can sustain its historically aggressive dividend increases.